PD-L1 in melanoma: facts and myths

Area of Science:

• Oncology
• Immunology
• Cancer Therapy

Background:

• Monoclonal antibodies targeting immune checkpoints are transforming cancer treatment.
• The PD-1/PD-L1 axis blockade is crucial for overcoming adaptive immune resistance.
• Recent advancements include its application in previously 'immune-unresponsive' solid tumors.

Purpose of the Study:

• To summarize the biological and clinical significance of PD-L1.
• To discuss PD-L1 in the context of immune checkpoint inhibitors.
• To highlight its therapeutic role in metastatic melanoma.

Main Methods:

• Perspective article synthesizing existing evidence.
• Review of biological mechanisms of PD-L1.
• Analysis of clinical relevance in cancer therapy.

Main Results:

• PD-1/PD-L1 axis blockade is a key strategy in cancer immunotherapy.
• Effective in metastatic melanoma and other solid malignancies like NSCLC, colorectal, renal cell, and head and neck cancers.
• Expands treatment options for tumors not traditionally considered immune-responsive.

Conclusions:

• PD-L1 plays a critical role in immune evasion and therapeutic response.
• Immune checkpoint inhibitors targeting PD-1/PD-L1 represent a significant advancement in oncology.
• Further understanding of PD-L1 is essential for optimizing cancer immunotherapy strategies.